60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare 60 Degrees Pharmaceuticals to similar companies based on the strength of its valuation, dividends, earnings, analyst recommendations, institutional ownership, profitability and risk.
Insider & Institutional Ownership
8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Volatility and Risk
60 Degrees Pharmaceuticals has a beta of 2.47, suggesting that its share price is 147% more volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals’ rivals have a beta of -0.04, suggesting that their average share price is 104% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and recommmendations for 60 Degrees Pharmaceuticals and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 60 Degrees Pharmaceuticals | 1 | 2 | 1 | 0 | 2.00 |
| 60 Degrees Pharmaceuticals Competitors | 7844 | 13796 | 25806 | 1039 | 2.41 |
60 Degrees Pharmaceuticals presently has a consensus target price of $13.85, suggesting a potential upside of 2,574.26%. As a group, “Pharmaceuticals” companies have a potential upside of 24.63%. Given 60 Degrees Pharmaceuticals’ higher probable upside, research analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than its rivals.
Profitability
This table compares 60 Degrees Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 60 Degrees Pharmaceuticals | -650.21% | N/A | -136.81% |
| 60 Degrees Pharmaceuticals Competitors | -2,398.26% | -203.62% | -15.08% |
Valuation and Earnings
This table compares 60 Degrees Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| 60 Degrees Pharmaceuticals | $1.41 million | -$7.36 million | -0.11 |
| 60 Degrees Pharmaceuticals Competitors | $3.55 billion | $3.17 billion | 562.76 |
60 Degrees Pharmaceuticals’ rivals have higher revenue and earnings than 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Summary
60 Degrees Pharmaceuticals rivals beat 60 Degrees Pharmaceuticals on 8 of the 12 factors compared.
60 Degrees Pharmaceuticals Company Profile
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for tropical and infectious diseases. The company’s work centers on treatments and preventive therapies for conditions that affect travelers, military personnel and populations in regions where infectious diseases are prevalent. Its lead product is Arakoda (tafenoquine), an oral prescription medicine approved by the U.S. Food and Drug Administration in 2018 for the prevention of malaria in adults.
Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
